

PROGRAM

MONDAY, 20 JUNE, 2016

WELCOME

8:45am - 9:10am

Hall A

KEYNOTE 1 - MARTIN EILERS

9:10am - 9:55am

Hall A

Chair: **Garrett Brodeur**

9:10am

Martin Eilers

Complexes of N-MYC and MYC with Aurora-A: an inroad to targeting MYC function for neuroblastoma therapy

abs# 1

PLENARY SESSION 1

9:55am - 10:30am

Hall A

Chairs: **William Weiss & Barbara Hero**

9:55am

Shoma Tsubota

The role of PRC2 in the early neuroblastoma tumorigenesis in *MYCN*-Tg mice

abs# 2

10:11am

Kevin Freeman

Transforming primary neural crest cells to model neuroblastoma reveals a lineage sensitivity to BET inhibitors

abs# 3

MORNING TEA

10:30am - 11:00am

Exhibition Area

PARALLEL 1 - ONCOGENESIS

11:00am - 12:30pm

Meeting room 1 & 2

Chairs: **Akira Nakagawara & Belamy Cheung**

- | | | |
|---------|--|--------|
| 11:00am | Miller Huang
Human pluripotent stem cell-based models of <i>MYCN</i> -amplified neuroblastoma | abs# 4 |
| 11:15am | Bieke Decaestecker
SOX11 acts as part of the MYCN regulatory protein complex implicated in neuroblastoma | abs# 5 |
| 11:30am | Shizhen (Jane) Zhu
Aberrant activation of SHP2 cooperates with MYCN in neuroblastoma pathogenesis | abs# 6 |
| 11:45am | Annick Mühlethaler-Mottet
The ALK-F1174L activating mutation mediates the upregulation of gene cluster located in the 15qD1 genomic region including the Myc locus in tumors derived from murine neural crest progenitor cells | abs# 7 |
| 12:00pm | Isabelle Janoueix-Lerosey
Activated ALK signals through the ERK-ETV5-RET pathway to drive neuroblastoma oncogenesis | abs# 8 |
| 12:15pm | Carol Thiele
Reactivation of cAMP /PKA pathway is an early event that relieves EZH2-mediated epigenetic suppression in High-Risk Neuroblastoma(HR-NB) | abs# 9 |

PARALLEL 2 - LIQUID BIOPSIES, CIRCULATING TUMOUR CELLS AND METASTASIS

11:00am - 12:30pm

Hall A

Chairs: **Frank Berthold & Klaus Beiske**

- | | | |
|---------|--|---------|
| 11:00am | Mathieu Chicard
Whole exome sequencing of circulating free tumour DNA for study of spatial and temporal tumor heterogeneity: accumulation of new mutations at tumor progression of neuroblastoma | abs# 10 |
| 11:15am | Martina Morini
Liquid biopsies reveal exosomal miRNA modulation in high-risk neuroblastoma patients after the induction therapy | abs# 11 |
| 11:30am | Katleen De Preter
Detection of copy number aberrations in cell free DNA from plasma of neuroblastoma patients using shallow massive parallel sequencing | abs# 12 |
| 11:45am | Fikret Rifatbegovic
The transcriptomic landscape of bone marrow-derived disseminated tumor cells of high-risk neuroblastoma patients | abs# 13 |
| 12:00pm | Alex BK Seong
A novel neuroblastoma metastatic mouse model identifies genes, pathways and drugs regulating metastasis | abs# 14 |
| 12:15pm | Giuseppe Barone
A native and immunocompetent <i>in vivo</i> model of chemorefractory, bone-marrow metastatic, "ultra-high risk" neuroblastoma. | abs# 15 |

LUNCH

12:30pm - 1:30pm

Exhibition Area

NEUROBLASTOMA CONSORTIUM MEETING

12:30pm - 1:30pm

Conference Room 5

INDUSTRY SPONSORED WORKSHOP: APEIRON

12:45pm - 1:25pm

Meeting room 1 & 2

R2 PLATFORM WORKSHOP: ONLINE PUBLIC RESOURCE FOR NEUROBLASTOMA OMICS DATA

12:50pm - 1:20pm

Hall A

PARALLEL 3 - TERT AND OTHER NOVEL TARGETS

1:30pm - 3:00pm

Hall A

Chairs: Jo Vandesompele & Arata Tomiyama

1:30pm	Andrea Kraemer The prognostic and therapeutic relevance of <i>TERT</i> activation in neuroblastoma	<i>abs# 16</i>
1:45pm	Eiso Hiyama Telomere biology in neuroblastoma: focusing on alteration of TERT promoter lesion	<i>abs# 17</i>
2:00pm	Balakrishna Koneru Constitutive activation of ATM kinase in neuroblastoma cell lines with the alternative lengthening of telomeres (ALT) phenotype induces resistance to DNA damaging agents	<i>abs# 18</i>
2:15pm	Rebecca Dagg A unique mechanism for the continual proliferation of high-risk neuroblastoma cells	<i>abs# 19</i>
2:30pm	Jessica Koach Targeting a novel MYCN onco-factor, PA2G4, for the treatment of neuroblastoma	<i>abs# 20</i>
2:45pm	Per Kogner Targeting tumor-promoting neuroblastoma microenvironment; Inhibition of tumor development and progression by therapy targeting mPGES-1 and prostaglandin E ₂ expression in cancer associated fibroblasts	<i>abs# 21</i>

PARALLEL 4 - NOVEL THERAPIES AND IMMUNOTHERAPY

1:30pm - 3:00pm

Meeting room 1 & 2

Chairs: Alex Swarbrick & Ro Bagatell

- | | | |
|--------|---|----------------|
| 1:30pm | Alessandro Quattrone
Targeting the LIN28B/let-7 axis by small molecules in neuroblastoma | <i>abs# 22</i> |
| 1:45pm | Meredith Irwin
A small molecule kinome inhibitor screen identifies the TGF-beta-activated kinase 1 (TAK1) as a target for combination therapy in MYC-driven neuroblastoma | <i>abs# 23</i> |
| 2:00pm | Vandana Batra
Preclinical characterization of meta-[²¹¹ At]astatobenzylguanidine ([²¹¹ At]MABG) as an alpha particle emitting systemic targeted radiotherapeutic for neuroblastoma | <i>abs# 24</i> |
| 2:15pm | Robyn T Sussman
A CD56 (NCAM1) targeting antibody-drug conjugate is potently effective in preclinical models of high-risk neuroblastoma | <i>abs# 25</i> |
| 2:30pm | Kristopher R Bosse
GPC2 is a putative oncogene and candidate immunotherapeutic target in high-risk neuroblastoma | <i>abs# 26</i> |
| 2:45pm | Shakeel Modak
Phase I study of anti-G _{D2} humanized 3F8 (hu3F8) monoclonal antibody (MAb) plus GM-CSF: High dosing and major responses in patients with resistant high-risk neuroblastoma (HR-NB) | <i>abs# 27</i> |

AFTERNOON TEA

3:00pm - 3:30pm

Exhibition Area

WORKSHOP 1 - EPIGENETIC REGULATION AND GENOME EDITING IN CANCER

3:30pm - 5:00pm

Hall A

Moderator: Frank Speleman

The study of epigenetic deregulation of cancer cells has moved to the forefront of cancer research as a result of the recent discovery that across all tumor entities roughly 20% of all mutations affect genes implicated in processes controlling methylation and chromatin modification. At the same time, an increasing number of novel epigenetic drugs are emerging and going through in vitro, pre-clinical and clinical testing. CRISPR/Cas technology has revolutionized controlled genome editing offering new exciting possibilities to investigate the complex epigenetic control of gene expression in cancer cells even down to the single cell level. In this workshop we bring together experts in this field explaining how new insights into the highly complex epigenetic regulatory processes can provide deeper understanding of tumor initiation, progression and therapy resistance and how genome editing can aid to further fuel this discovery process, ultimately providing us the tools and data to identify novel drug targets and therapeutic strategies to combat neuroblastoma.

3:30pm

Stanley Qi

CRISPR/Cas9 based genome editing

4:00pm

Tim Mercer

Putting genes under the microscope: an exploration of the human transcriptome

4:20pm

Kevin Freeman

Exploring the role of chromatin remodeling factors in neuroblastoma oncogenesis using genome-editing of mice neural crest progenitors

4:32pm

Jason Shoet

Defining epigenetic drug targets in neuroblastoma; structure is function

4:44pm

Round Table Discussion

WORKSHOP 2 - NOVEL CLINICAL TRIAL DESIGN FOR ADVANCED NEUROBLASTOMA: A DEBATE

3:30pm - 5:00pm

Meeting room 1 & 2

Moderator: Glenn Marshall

Much of the pre-clinical and clinical research on neuroblastoma is aimed at discovering more effective therapy for the majority of children who present with clinically advanced disease. Even successful current therapy for advanced neuroblastoma can lead to severe short and longterm side-effects, indicating the need for improved treatment strategies. Recent advances in organic chemistry and structure-aided design have seen a marked increase in the number of available targeted anticancer drugs, but the relative rarity of neuroblastoma may mean that novel trial designs are required to more rapidly incorporate pre-clinical advances into frontline protocols. This significant shift, coupled with more sophisticated methods of minimal residual disease monitoring, techniques for detailed analysis of tumor heterogeneity and 'window therapy' trial designs used to assess treatment efficacy in real-time, suggest that traditional single comparison phase 3 trial designs may no longer be suited to the problem of incorporating promising single agent or combination therapies into the treatment of newly diagnosed patients. The advent of precision or personalised oncologic medicine, aimed at better matching the treatment to the target holds the promise of improved cure rates and lower side-effect profiles. However, the relatively low number of genomic targets in neuroblastoma and the poor availability of novel agents for paediatric patients, means the field faces significant clinical research challenges in the future. We have asked the leaders of frontline international Phase 3 clinical trials for advanced neuroblastoma and early phase trialists to debate the following hypothesis: "That a conventional single comparison, randomised, Phase 3 trial design is no longer appropriate for newly diagnosed advanced neuroblastoma patients".

3:30pm **Introductory remarks**

3:35pm **Pre-debate Voting**

3:40pm **Ruth Ladenstein**

Chair, SIOPEN-HR1; St. Anna Kinderkrebsforschung e.V. & Children's Cancer Research Institute
Vienna, Austria

3:55pm **Julie Park**

Chair, COG Neuroblastoma Steering Committee; Seattle Childrens Hospital & University of
Washington, Seattle, USA

4:10pm **Angelika Eggert**

Chair, German Neuroblastoma Trial Group; Charité Universitätsmedizin Berlin, Germany

4:25pm **David Ziegler**

Co-Chair, NANT Phase I/II DFMO trial; Sydney Children's Hospital, Sydney Australia

4:40pm **Questions from the floor**

4:55pm **Post-debate voting**

RAPID FIRE POSTER PRESENTATION 1

5:05pm - 5:25pm

Hall A

- Christine Gana**
New, highly selective MRP1 inhibitors show promising preclinical activity in neuroblastoma abs# 249
- Hedi Deubzer**
The MCM complex is a critical node in the miR-183 signaling network of *MYCN*-amplified neuroblastoma cells abs# 188
- Lara Riehl**
The mitochondrial genetic landscape in neuroblastoma from tumor initiation to relapse abs# 198
- Sela T Po'uha**
Stathmin expression regulates miR-382/PTPN14 expression in neuroblastoma cells abs# 256
- Giuseppe Giannini**
The MRN complex controls replication stress and allows proliferation and survival in *MYCN* amplified neuroblastoma abs# 250
- Robyn T Sussman**
CAMKV is a candidate immunotherapeutic target in *MYCN*-amplified neuroblastoma. abs# 226
- Amos HP Loh**
Proteomic analysis of high-risk neuroblastoma identifies nuclear distribution protein C as a marker of differentiation and prognosis abs# 177
- Laurel T. Bate-Eya**
EZH2 is highly expressed in neuroblastoma and plays an important role in neuroblastoma cell survival independent of its histone methyltransferase activity. abs# 187
- Godelieve Tytgat**
Circulating tumor DNA for disease monitoring in neuroblastoma abs# 171
- W. Clay Gustafson**
Aurora Kinase A inhibition sensitizes neuroblastoma to ¹³¹I -MIBG abs# 173
- Navin Pinto**
Isolation of circulating tumour and associated cells by microfiltration in patients with neuroblastoma abs# 169
- Barbara Hero**
Survival tree analysis of an independent cohort reveals risk factors as proposed in the INRG system abs# 162
- Claudia Pasqualini**
Survival and prognostic factors for children 12 to 18 months of age with stage 4 non-*MYCN* amplified neuroblastoma treated in the SIOPEX high-risk trial abs# 168
- Shakeel Modak**
Phase II study of the combination of bevacizumab plus irinotecan and temozolomide for relapsed or refractory neuroblastoma abs# 221
- Ulrike Pötschger**
Impact of age and *MNA* amplification (MNA) on long-term survival rates: accurate estimation and refined modeling using innovative statistical approaches. A SIOPEX study from the high risk neuroblastoma trial HR-NBL1/SIOPEX. abs# 170
- Alvin Kamili**
Ex vivo drug screening as a strategy for personalised therapy in high-risk neuroblastoma abs# 174

POSTER SESSION 1 WITH WINE & CHEESE

5:25pm - 7:00pm

Hall C + D

For those with specific interest in abstracts from the Basic, Clinical or Translational categories please use the lists located on page 129 as you walk amongst the posters to find them easily. Posters are arranged in the Exhibition Area in consecutive numerical order. Should you wish to view the entire list of poster abstracts in either Basic, Clinical or Translation divisions, please refer to the 'app' where you will find the posters sorted by category. Further information on the 'app' is available on page 22. Below is a complete listing of all posters in the Monday evening poster session.

Sponsored by



M. Reza Abbasi

Impact of bone marrow-derived disseminated neuroblastoma cells on the identification of the relapse seeding clone

abs# 151

Shifra Ash

Analyzing risk factors for stem-cell collection failure in patients on the High-Risk Neuroblastoma 1 trial (HR-NBL1/SIOPEN)

abs# 152

Klaus Beiske

Quantification of bone marrow disease in high risk neuroblastoma patients by anti-GD2 immunocytochemistry – impact on survival. A SIOPEN High Risk Study

abs# 153

Pablo Berlanga

Central imaging review in the SIOPEN high-risk neuroblastoma trial: preliminary data on central nervous system recurrences

abs# 154

Frank Berthold

Characteristics and risk factors of 517 patients with first recurrence from stage 4 neuroblastoma over 18 months

abs# 155

Sue A Burchill

Detection of PHOX2B and TH mRNA by RTqPCR in peripheral blood stem cell harvests may identify children with stage 4 neuroblastoma that have an increased risk of an event post reinfusion: a SIOPEN study

abs# 156

Louis Chesler

Genome-wide analysis of liquid biopsies reveals a novel layer of tumor heterogeneity in neuroblastoma

abs# 157

Valérie Combaret

Detection of tumor *ALK* Status in neuroblastoma patients using peripheral blood

abs# 158

Susanne Fransson

Amplification of *CDK4* and *MDM2* is associated with atypical clinical features in high risk neuroblastoma patients

abs# 159

Mark N Gaze

A comparison of ¹²³I-mIBG planar imaging and SPECT/CT with ⁶⁸Ga-DOTATATE PET/CT for staging and response assessment of high-risk neuroblastoma

abs# 160

Jo Lynne Harenza

Development of a targeted sequencing panel for detection of subclonal mutations in neuroblastoma at diagnosis

abs# 161

Barbara Hero

Survival tree analysis of an independent cohort reveals risk factors as proposed in the INRG system

abs# 162

MoonSun Jung

An 18-gene Myc activity signature predicts poor clinical outcome in multiple Myc-associated cancer types

abs# 163

Denis Kachanov

Opsoclonus myoclonus syndrome in children with neuroblastoma

abs# 164

Natalia M Khranovska

Prognostic and predictive significance of *p53*, *MDM2* and miRNAs gene expression in patients with neuroblastoma

abs# 165

Teofila Książek

Microarray CGH analysis of genomic imbalances in neuroblastoma FFPE specimens – pilot study

abs# 166

Noritaka Miyazawa

- Clinical characteristics and risk factor of transplantation-associated microangiopathy (TAM) in high-risk neuroblastoma undergoing autologous peripheral blood stem cell transplantation (auto-PBSCT) abs# 167
- Claudia Pasqualini**
- Survival and prognostic factors for children 12 to 18 months of age with stage 4 non-*MYCN* amplified neuroblastoma treated in the SIOPEX high-risk trial abs# 168
- Navin Pinto**
- Isolation of circulating tumor and associated cells by microfiltration in patients with neuroblastoma abs# 169
- Ulrike Pötschger**
- Impact of age and *MNA* amplification (MNA) on long-term survival rates: accurate estimation and refined modeling using innovative statistical approaches. A SIOPEX study from the high risk neuroblastoma trial HR-NBL1/SIOPEX. abs# 170
- Godelieve Tytgat**
- Circulating tumor DNA for disease monitoring in neuroblastoma abs# 171
- Jalenka van Wijk**
- A flow cytometry backbone panel as a first step in detection of circulating tumor cells in neuroblastoma abs# 172
- W. Clay Gustafson**
- Aurora Kinase A inhibition sensitizes neuroblastoma to ^{131}I -MIBG abs# 173
- Alvin Kamili**
- Ex vivo* drug screening as a strategy for personalised therapy in high-risk neuroblastoma abs# 174
- Daisuke Kaneda**
- A novel histone deacetylase inhibitor OBP-801 induces apoptosis in neuroblastoma tumor cells abs# 175
- Loretta MS Lau**
- Serum C-circles as biomarker of Alternative Lengthening of Telomeres (ALT) in neuroblastoma abs# 176
- Amos HP Loh**
- Proteomic analysis of high-risk neuroblastoma identifies nuclear distribution protein C as a marker of differentiation and prognosis abs# 177
- Ferro Nguyen**
- Targeted drug delivery using nanoparticles (NPs) in neuroblastoma (NB) xenografts abs# 178
- Maike Nortmeyer**
- Bromodomain-inhibition as therapeutic option for *MYCN*-amplified neuroblastoma abs# 179
- Jed G Nuchtern**
- The Connectivity Map bioinformatics platform identifies agents that reverse the chemotherapy resistance phenotype in neuroblastoma abs# 180
- Alessandro Quattrone**
- A screening for natural products identifies a flavonol as a synergistic compound with 13-*cis* retinoic acid in neuroblastoma abs# 181
- Nilay Shah**
- CYP26-mediated metabolism of retinoids is a putative mechanism of treatment resistance in neuroblastoma abs# 182
- Justine Stehn**
- Anti-tropomyosin agents enhance the antitumor effectiveness of microtubule inhibitors in preclinical models of neuroblastoma abs# 183
- Carol J Thiele**
- Inhibition of STAT3 with the generation 2.5 antisense oligonucleotide, AZD9150, decreases tumor-initiating potential of neuroblastoma cells and increases their chemosensitivity abs# 184
- Hiroyuki Yoda**
- Targeting the *MYCN* oncogene in *MYCN*-amplified neuroblastoma with a novel PI polyamide DNA-alkylating drug conjugate abs# 185
- Libo Zhang**
- Combined antitumor therapy with metronomic administration of topotecan and hypoxia-activated prodrug, evofosfamide, in neuroblastoma preclinical models abs# 186
- Laurel T. Bate-Eya**
- EZH2 is highly expressed in neuroblastoma and plays an important role in

- neuroblastoma cell survival independent of its histone methyltransferase activity *abs# 187*
Hedi Deubzer
- The MCM complex is a critical node in the miR-183 signaling network of *MYCN*-amplified neuroblastoma cells *abs# 188*
Moritz Gartlgruber
- A genome-wide *MYCN* synthetic lethal screen identifies inhibition of PRC2 as drug target in *MYCN*-amplified neuroblastoma cells *abs# 189*
Venkatadri Kolla
- Epigenetic silencing of *CHD5* expression by histone modification in human neuroblastoma *abs# 190*
Jan Koster
- R2: A public user-friendly website for integrated analysis of genomic data and associated clinical parameters in neuroblastoma *abs# 191*
Tim Lammens
- Non-random pattern of whole chromosome gains and losses in neuroblastoma with numerical chromosomal aberrations *abs# 192*
Koumudi Naraparaju
- Role of MiRNAs in the epigenetic silencing of *CHD5*, a tumor suppressor in neuroblastoma (NB) *abs# 193*
Miki Ohira
- Clinical relevance of genomic and epigenomic classification of *MYCN*-non-amplified neuroblastoma *abs# 194*
Miki Ohira
- Genomic characterization of high-risk neuroblastoma in Japan: A retrospective study of 537 cases by using updated follow-up data based on INRG variables [Japan Neuroblastoma Study Group (JNBSG)] *abs# 195*
Chi Yan Ooi
- MicroRNA-204 suppresses neuroblastoma tumour growth through down-regulation of *MYCN* oncogene *abs# 196*
Alessandro Quattrone
- Exploring m6A mRNA methylation for novel therapeutic chances in neuroblastoma *abs# 197*
Lara Riehl
- The mitochondrial genetic landscape in neuroblastoma from tumor initiation to relapse *abs# 198*
Ya-Hui Tsai
- CPEB1 down-regulated the expression of *MYCN* *via* tumor-suppressor miRNA let-7 in human neuroblastoma cells *abs# 199*
Kumiko Uryu
- Genetic characteristics of 494 neuroblastomas using genome-wide analysis combined with immunohistochemistry *abs# 200*
David Cantelmi
- End of life care for children with neuroblastoma: a retrospective study from the Royal Children Hospital Brisbane *abs# 201*
Angela Cha
- Physéal arrest leading to angular deformity after therapy with isotretinoin for high risk neuroblastoma (HR-NBL) *abs# 202*
- Hsiu-Hao Chang**
 A multidisciplinary team care improved outcomes for children with high-risk neuroblastoma *abs# 203*
- Matthew D Aldridge**
 The requirement for accurate standardization and methodology of dosimetry in international trials incorporating molecular radiotherapy (MRT) in the treatment of high-risk neuroblastoma *abs# 204*
- Stephane Birkle**
 Antibodies specific for O-acetyl-GD2 mediates the same efficient anti-neuroblastoma effects as therapeutic ch14.18 antibody to GD2 without antibody induced allodynia *abs# 205*
- Tom Boterberg**

- Importance of quality assurance in radiotherapy for optimal local control. A report from the SIOPEX radiotherapy committee of the High Risk Neuroblastoma Trial (HR-NBL1/SIOPEX) abs# 206
- Bao C Bui**
Stromal collagen type XI alpha 1 COL11A1 expression in neuroblastoma abs# 207
- Angela Cha**
Dinutuximab combined with chemotherapy in patients with multiply relapsed/refractory high risk neuroblastoma (HR-NBL) abs# 208
- Godfrey CF Chan**
Evaluation of genetic modified anaerobic *Salmonella* typhimurium as therapy for neuroblastoma: Comparison of response of orthotopic mouse models with different immunological backgrounds abs# 209
- Maria V Corrias**
Preclinical studies of anti-PDL-1/PD-1-based combination immunotherapy for Neuroblastoma abs# 210
- Eoin Dodson**
Which miRNAs should be developed into novel therapeutics for neuroblastoma? abs# 211
- Christin Eger**
Generation and characterization of a new chimeric human/mouse anti-idiotypic antibody ganglidiximab for active immunotherapy against neuroblastoma abs# 212
- Barbara Hero**
Role of Surgery in Patients older than 18 months with localized Neuroblastoma (Stage 1-3) abs# 213
- Meredith Irwin**
More is less: radiation exposure to family caregivers and health care providers of paediatric neuroblastoma patients receiving ¹³¹I-MIBG therapy in Canada abs# 214
- Eugene S Kim**
Anti-GD2 antibody combined with activated natural killer cells leads to improved survival and decreased metastasis in a minimal residual disease mouse model of neuroblastoma abs# 215
- Li-Ling Lin**
TLR3-Mediated innate immune response in the treatment of neuroblastoma abs# 216
- Holger Lode**
Interleukin-2 adds toxicity to long term infusion treatment regimen of ch14.18/CHO antibody without measurable additional activity in relapsed/refractory neuroblastoma patients abs# 217
- Hans Loibner**
Galactose- α -1,3-galactose (a-Gal) glycosylation determinant on ch14.18 antibodies produced by CHO- or SP2/0 cell lines – potential clinical impact abs# 218
- Suzanne P MacFarland**
Entrectinib is a potent inhibitor of Trk-driven neuroblastomas in a xenograft mouse model abs# 219
- Kimikazu Matsumoto**
Impact of radiotherapy and curie score on bone relapse in high-risk neuroblastoma abs# 220
- Shakeel Modak**
Phase II study of the combination of bevacizumab plus irinotecan and temozolomide for relapsed or refractory neuroblastoma abs# 221
- Shakeel Modak**
Event-free survival (EFS) and overall survival (OS) of *MYCN*-amplified stage 2/3 neuroblastoma with or without autologous stem-cell transplantation (ASCT) abs# 222
- Jan Molenaar**
The iTHER (individualized THERapy) program; personalized cancer treatment for relapsed pediatric cancer abs# 223
- Lucas Moreno**
The BEACON-Neuroblastoma ITCC/SIOPEX phase 2 trial for children with relapsed and refractory neuroblastoma: a progress report abs# 224
- Daniel A Morgenstern**
Viability Of cryopreserved peripheral blood stem cells (PBSC) does not guarantee functional activity: important implications for quality assurance of stem cell transplant programmes abs# 225

- Robyn T Sussman**
CAMKV is a candidate immunotherapeutic target in *MYCN*-amplified neuroblastoma abs# 226
- Yoshiyuki Takahashi**
Significantly reduced relapse rate after KIR ligand incompatible allogeneic cord blood transplantation with nonmyeloablative conditioning for primary stage IV neuroblastoma abs# 227
- Domonique Valteau-Couanet**
Validation of a test-dose strategy prior intravenous melphalan in children with renal failure undergoing high-dose chemotherapy with autologous stem cell transplantation abs# 228
- Orazio Vittorio**
Dextran-Catechin conjugate targets copper metabolism in neuroblastoma abs# 229
- Saurabh Agarwal**
Development of a novel transgenic neuroblastoma tumor model using genome editing abs# 230
- Jessica L Bell**
IGF2BP1 harbours prognostic significance by gene gain, diverse expression and interplay with *MYCN* abs# 231
- Annick Mühlethaler-Mottet**
Aldehyde dehydrogenases activity plays a key role in NB aggressive behavior abs# 232
- Noriyuki Nishimura**
Rab6B mediates the progression of neuroblastoma through the interaction with MTMR5 abs# 233
- Camilla Persson**
Characterization of patient-derived xenograft neuroblastoma cells abs# 234
- Anna Philpott**
Differentiation of Neuroblastoma is controlled by cdk-mediated regulation of the master regulator transcription factor *Ascl1*. abs# 235
- Diogo Ribeiro**
MYCN-regulated nuclear hormone receptors impact differentiation and survival in neuroblastoma patients abs# 236
- Hisanori Takenobu**
CDX1 regulates cancer stemness pathway in neuroblastoma abs# 237
- Yasutoshi Tatsumi**
BMCC1, a tumor suppressor protein that facilitates DNA-damage response and apoptosis, is associated with favorable prognosis of neuroblastoma abs# 238
- Nobuyuki Yamamoto**
DENN domain protein *DENND2A* regulates the progression of neuroblastoma abs# 239
- Saurabh Agarwal**
Transmembrane adaptor protein *PAG1* is a novel tumor suppressor in neuroblastoma abs# 240
- Mark A Applebaum**
The identification of hypoxia regulated genes that confer a poor prognosis in neuroblastoma patients abs# 241
- Michael B Armstrong**
The MAD Family members, *MXI1* and *MXI0*, display distinct subcellular localization patterns in neuroblastoma abs# 242
- Michael B Armstrong**
The expression of *Mxi1* and *Mxi0* lead to differential effects on neuroblastoma pathogenesis and chemosensitivity. abs# 243
- Eveline Barbieri**
Targeting *MYCN*-amplified neuroblastoma through *ROR α* activation. abs# 244
- Christina L. Chang**
Identification of a novel protein that suppresses the ability of *NDPK-A* to promote the invasiveness of neuroblastoma cells abs# 245
- Jorida Coku**
Reduced endoplasmic reticulum (ER)-mitochondria tethering as a cause of multidrug resistance in neuroblastoma abs# 246

Katleen De Preter

An embryonic stem cell activated FOXM1 transcriptional program marks ultra-high-risk primary neuroblastoma patients for FDI-6 small molecule inhibition

abs# 247

Han-Fei Ding

Molecular control of neuroblastoma stem cell metabolism

abs# 248

Christine Gana

New, highly selective MRP1 inhibitors show promising preclinical activity in neuroblastoma

abs# 249

Giuseppe Giannini

The MRN complex controls replication stress and allows proliferation and survival in MYCN amplified neuroblastoma

abs# 250

Dana-Lynn Koomoa

TRPM7 promotes Neuroblastoma progression

abs# 251

Jacqueline M Kraveka

Curcumin mediated apoptosis in human neuroblastoma cells via ROS and inhibition of sphingomyelin synthase and glycosylceramide synthase

abs# 252

Yuanyuan Li

PPP3CB is a novel prognostic indicator of high-risk neuroblastoma contributing to aggressive behaviors

abs# 253

Martina Morini

Clinical significance of a seven-gene hypoxia signature in neuroblastoma

abs# 254

Annick Mühlethaler-Mottet

The CXCR4/CXCR7/CXCL12 axis is involved in a secondary but complex control of neuroblastoma metastatic cell homing

abs# 255

Sela T Po'uha

Stathmin expression regulates miR-382/PTPN14 expression in neuroblastoma cells

abs# 256

Rachele Rosati

Functional Genomics identifies novel therapeutic targets for retinoic acid combinations

abs# 257

Miriam Rosenberg

A multidisciplinary approach to antigen discovery and immune profiling of Opsoclonus-Myoclonus Ataxia Syndrome associated with Neuroblastoma

abs# 258

Hervé Sartelet

Composite Neuroblastoma: Unique tumours with morphologically and genetically defined intratumoral heterogeneity

abs# 259

Yuting Sun

The histone H3 lysine 4 presenter WDR5 is a potential therapeutic target in N-Myc-induced neuroblastoma.

abs# 260

Arata Tomiyama

The signaling complex of tyrosine phosphatase SHP2 and docking protein ShcC regulates oncogenicity of neuroblastoma cells in a tyrosine-phosphorylation dependent manner.

abs# 261

Catarina Trager

The role of p75^{NTR} during neuronal differentiation of neuroblastoma cells

abs# 262

WELCOME FUNCTION – FOOD & WINE INCLUDED

7:00pm - 9:00pm

Outdoor Plaza

PROGRAM

TUESDAY, 21 JUNE, 2016

KEYNOTE 2 - NEAL ROSEN

8:30am - 9:15am

Chair: Kate Matthay

Hall A

8:30am

Neal Rosen

Not available at time of print

abs# 33

PLENARY SESSION 2

9:15am - 10:20am

Chairs: Mike Hogarty & Murray Norris

Hall A

9:15am

Suzanne Vanhauwaert

The *BRIP1/FANCD1* DNA helicase is a druggable 17q driver oncogene involved in G-quadruplex induced replicative stress resistance in neuroblastoma

abs# 34

9:31am

Saurabh Agarwal

MLL1 and JMJD3 regulate neuroblastoma cancer stem cells

abs# 35

9:47am

Liselot Mus

Sensing mutant ALK: capicua and ETV5 as executors of aberrant ALK-driven MAPK signaling in neuroblastoma

abs# 36

10:03am

Jan Koster

TERT rearrangements are frequent in neuroblastoma and identify aggressive tumours

abs# 37

INRG PRESENTATION

10:20am - 10:30am

Hall A

10:20am

Samuel L Volchenbom

INRG Data Commons – A User Journey

abs# 38

MORNING TEA

10:30am - 11:00am

Exhibition Area

PARALLEL 5 - EPIGENETICS

11:00am - 12:30pm

Meeting room 1 & 2

Chairs: Carol Thiele & Takehiko Kamijo

- 11:00am **Frank Westermann**
Integrative genome-scale analysis identifies epigenetic mechanisms of transcriptional deregulation in unfavorable neuroblastomas *abs# 39*
- 11:15am **Isabelle Janoueix-Lerosey**
Dissecting neuroblastoma specific regulatory networks through epigenome mapping and transcriptional profiling of neuroblastoma and neural crest cell lines *abs# 40*
- 11:30am **Eveline Barbieri**
The histone chaperone CHAF1A promotes tumorigenesis and opposes neuroblastoma differentiation via metabolic reprogramming. *abs# 41*
- 11:45am **Bieke Decaestecker**
The TBX2 super-enhancer marked transcription factor on 17q is overexpressed in neuroblastoma and infers poor prognosis *abs# 42*
- 12:00pm **Shana Claeys**
The HBP1 tumor suppressor is a negative epigenetic regulator of MYCN driven neuroblastoma through interaction with the PRC2 complex. *abs# 43*
- 12:15pm **Tao Liu**
Combination therapy with the bromodomain inhibitor JQ1 and the histone deacetylase inhibitor panobinostat synergistically reduce LIN28B gene and N-Myc protein expression and suppress neuroblastoma progression *abs# 44*

PARALLEL 6 - TRANSLATIONAL AWARDS SESSION

11:00am - 12:30pm

Hall A

Chairs: John Maris & Matthias Fischer

- 11:00am **Angela Bellini**
High frequency of mutations in chromatin remodeling genes in neuroblastoma *abs# 45*
- 11:15am **Melinda Halasz**
Identification of spliceosomal components as novel therapeutic targets for the treatment of high-risk, MYCN-driven neuroblastoma *abs# 46*
- 11:30am **Evon Poon**
The orally bioavailable small molecule CDK9 inhibitors CYC065 and CCT68127 are potent inhibitors of MYCN transcription *abs# 47*
- 11:45am **Paul J Wood**
Long term, continuous exposure to panobinostat induces terminal differentiation and long term survival in the TH-NMYC neuroblastoma mouse model *abs# 48*
- 12:00pm **Renata Sano**
A novel antibody-drug conjugate directed to the ALK receptor demonstrates efficacy in models of neuroblastoma *abs# 49*
- 12:15pm **Kellie Haworth**
Oncolytic herpes Simplex-1 virotherapy augments chimeric antigen receptor T-Cell (CAR-T) therapy in Neuroblastomas *abs# 50*

LUNCH

12:30pm - 1:30pm

Exhibition Area

ANRA ADVISORY BOARD MEETING

12:30pm - 1:30pm

Meeting room 1 & 2

PARALLEL 7 - BASIC AWARDS SESSION

1:30pm - 3:00pm		Hall A
Chairs: Rogier Versteeg & Darrell Yamashiro		
1:30pm	Joanna Kitlinska Prenatal stress increases NB tumorigenicity in TH-MYCN mice.	abs# 51
1:45pm	Daniel R Carter Identifying mechanisms of neuroblastoma tumorigenesis using single cell transcriptomics	abs# 52
2:00pm	Michael Hogarty <i>ARID1A</i> and <i>ARID1B</i> mutations in the Swi/Snf BAF chromatin remodeling complex drive poor outcome neuroblastoma	abs# 53
2:15pm	Matthias Fischer Identification of somatic mutations determining the neuroblastoma phenotype	abs# 54
2:30pm	Hedi Deubzer MYCN and HDAC5 transcriptionally repress <i>CD9</i> to trigger an invasion-metastasis cascade in neuroblastoma	abs# 55
2:45pm	Gonzalo Lopez <i>MYCN</i> amplified neuroblastomas require TEAD4 to orchestrate transcriptional programs, exposing a therapeutic vulnerability	abs# 56

PARALLEL 8 - CLINICAL IMAGING, RISK FACTORS AND RESPONSE

1:30pm - 3:00pm Meeting room 1 & 2
Chairs: Dominique Valteau-Couanet & Wendy London

1:30pm	Steven G. DuBois Clinical, biologic, and outcome differences according to MIBG avidity in children with neuroblastoma: A report from the Children's Oncology Group (COG)	abs# 57
1:45pm	Shakeel Modak Discordance in ¹²³ I-MIBG (MIBG) and ¹⁸ F-FDG positron emitting tomography (PET) scans after multimodality therapy for high-risk neuroblastoma: clinical implications	abs# 58
2:00pm	Yen-Lin Liu Diagnostic FDG and FDOPA positron emission tomography scans distinguish the genomic type and treatment outcome of neuroblastoma	abs# 59
2:15pm	Daniel A Morgenstern Towards a model for risk stratification of high-risk neuroblastoma. A report from the HR-NBL-1/SIOPEN study.	abs# 60
2:30pm	Julie R. Park Revisions to the International Neuroblastoma Response Criteria: A consensus statement from the NCI-Clinical Trials Planning Meeting	abs# 61
2:45pm	Barbara Hero Risk factors for outcome after relapse or progression of localized Neuroblastoma	abs# 62

AFTERNOON TEA

3:00pm - 3:30pm Exhibition Area

WORKSHOP 3 - EMERGING TECHNOLOGIES FOR EXPLORATION OF TUMOR HETEROGENEITY, CLONAL EVOLUTION AND PROGRESSION IN NEUROBLASTOMA

3:30pm - 5:00pm

Moderator: Gudrun Schleiermacher

Hall A

Sponsored by



Genetic heterogeneity and clonal evolution have been shown to play a role in progression of neuroblastoma. Recent data from other malignancies suggest that genetic heterogeneity might reflect not only evidence of competing clones, but also cooperating clonal events. This workshop will focus on neuroblastoma genetic heterogeneity, seeking to explore how recent and emerging technologies such as single cell studies and surrogate samples including circulating tumor DNA (ctDNA) and disseminated/circulating tumor cells (DTC/CTC) and can contribute to the understanding of the role of genetic heterogeneity and clonal evolution in tumor progression. While highlighting technical issues, challenges and pitfalls, the important questions of how these findings can be harnessed for clinical management of neuroblastoma patients will be further discussed.

- 3:30pm **Spyros Darmanis**
Single cell studies of the brain and its malignancies
- 4:00pm **John Maris**
The biological and clinical relevance of tumoral heterogeneity and clonal evolution in high-risk neuroblastoma
- 4:15pm **M. Reza Abbasi**
Impact of bone marrow-derived disseminated neuroblastoma cells on the identification of the relapse seeding clone
- 4:30pm **Angelika Eggert**
Addressing tumor heterogeneity in NB - potential and challenges of liquid biopsies
- 4:45pm **Panel Discussion**

WORKSHOP 4 - NEXT GENERATION RISK STRATIFICATION: NEW APPROACHES TO IDENTIFY HIGHEST RISK PATIENTS (OR ULTRA HIGH RISK PATIENTS)

3:30pm - 5:00pm

Meeting room 1 & 2

Moderator: Meredith Irwin

Risk stratification approaches that rely on robust clinical and biological prognostic factors have been used to predict outcome and tailor therapies for neuroblastoma patients for more than two decades. Current classification systems utilize clinical, histologic, and genetic factors to identify patients with low, intermediate, or high risk neuroblastoma. Recent advances have resulted in improved patient outcomes; however, long-term survival for high-risk patients remains < 50%. Furthermore, current prognostic factors do not predict which high-risk (HR) neuroblastoma patients will fail to achieve remission with current era therapies. There are many efforts aimed at prospectively identifying the subset of HR patients at highest risk of death, or "ultra-high risk (UHR) patients," for whom novel therapies may be indicated early on in the course of the disease. Currently there is no uniform definition for UHR and to date, no clinical or genetic determinant(s) reliably identify UHR patients. In this workshop we will highlight recent advances in the discovery of germline and somatic genomic alterations that may predict poor outcome or failure to respond to therapy in the setting of high-risk disease. The potential roles for gene expression signatures and detection of minimal residual disease will also be discussed. Following these presentations there will be a panel discussion to consider how to incorporate these novel prognostic factors into upfront clinical trials and how we may use genomic markers and minimum residual disease status together with current prognostic factors to further refine the next generation of risk classification systems.

3:30pm **Introduction, overview and goals**

3:35pm **Sharon Diskin**

Can germline and somatic mutations (or rare variants) help us identify "ultra-high risk" neuroblastoma and predict patient outcomes?

3:50pm **Katleen De Preter**

Copy number profiles as prognostic marker for high-risk neuroblastoma patients

4:05pm **Matthias Fischer**

Molecular risk stratification of neuroblastoma patients - using RNA, DNA, or both?

4:20pm **Sue Burchill**

Clinical impact and technical application of reverse transcriptase polymerase chain reaction to detect neuroblastoma RNAs in bone marrow and blood

4:40pm **Panel Discussion**

RAPID FIRE POSTER PRESENTATION 2

5:05pm - 5:25pm

Hall A

Sharon J. Diskin

Common germline variants at *MLF1* and *CPZ* loci associated with neuroblastoma susceptibility

abs# 295

Tao Liu

Suppressing the expression of a single novel long noncoding RNA leads to neuroblastoma regression or eradication

abs# 298

Shinichi Kiyonari

Identification of new synthetic lethal genes in *MYCN*-amplified neuroblastoma cells

abs# 363

Zhi Xiong Chen

A non-canonical tumor suppression pathway identified in neuroblastoma – A New Paradigm for Personalized Treatment and Prognosis

abs# 349

Ji Won Lee

Comprehensive analysis of neuroblastoma using high depth cancer gene panel sequencing

abs# 297

Michael M Song

Cell lines (CLs) and patient derived xenografts (PDXs) established from post-mortem neuroblastoma samples display heterogeneity in sensitivity to chemotherapeutic agents commonly utilized in the treatment of high-risk neuroblastoma patients

abs# 293

Keri A Streby

Enhancing ¹³¹I-MIBG radiation therapy with oncolytic HSV1716 and NAT gene therapy in high-risk neuroblastoma

abs# 294

Giuseppe Barone

The CHK1 inhibitor CCT244747, alone and in combination with gemcitabine, is active against p53 deficient models of neuroblastoma resistant to chemotherapy

abs# 283

Daniel A Morgenstern

Engraftment following busulfan/melphalan (BuMel) high-dose chemotherapy for high-risk neuroblastoma. A report from the HR-NBL-1/SIOPEN trial

abs# 326

Godelieve Tytgat

¹³¹Iodine-metaiodobenzylguanidine (¹³¹I-MIBG) and autologous stem cell transplantation harvesting and hematological reconstitution in high-risk neuroblastoma patients

abs# 335

Ruth Ladenstein

Prognostic Factors in stage 4 neuroblastoma patients treated with Busulphan-Melphalan. Report from the European High Risk Neuroblastoma HR-NBL1/SIOPEN Trial

abs# 324

Matthew D Aldridge

Establishment of a reproducible methodology and results for molecular radiotherapy dosimetric assessment of ¹⁷⁷Lu-DOTATATE in neuroblastoma

abs# 312

Hiroyuki Shichino

Phase I trial of perifosine monotherapy in patients with relapsed or refractory neuroblastoma

abs# 331

Gareth Veal

Busulfan and melphalan pharmacokinetics in high-risk neuroblastoma patients treated on the HR-NBL1/SIOPEN trial

abs# 308

Gudrun Schleiermacher

Genomic profiling using circulating free tumor DNA highlights heterogeneity in neuroblastoma

abs# 301

Laurel T. Bate-Eya

High efficacy of the BCL-2 inhibitor venetoclax (ABT-199) in neuroblastoma and rational for combination therapy

abs# 284

Min Kang

Pharmacokinetics (PK) of 13-cis Retinoic Acid in COG Phase III Neuroblastoma Studies

abs# 321

POSTER SESSION 2 WITH WINE & CHEESE

5:25pm - 7:00pm

Hall C + D

For those with specific interest in abstracts from the Basic, Clinical or Translational categories please use the lists located on page 129 as you walk amongst the posters to find them easily. Posters are arranged in the Exhibition Area in consecutive numerical order. Should you wish to view the entire list of poster abstracts in either Basic, Clinical or Translation divisions, please refer to the 'app' where you will find the posters sorted by category. Further information on the 'app' is available on page 22. Below is a complete listing of all posters in the Tuesday evening poster session.

Sponsored by



Boris Decarolis

Impact of the involvement of the separate body regions in the modified Curie and the SIOPEX mIBG-scoring systems in patients with stage 4 neuroblastoma

abs# 263

Alexander E. Druy

Prognostic significance of imbalanced chromosomal alterations in primary and recurrent neuroblastoma

abs# 264

Shakeel Modak

¹⁸F-Meta Fluorobenzyl Guanidine (MFBG) Positron Emission Tomography(PET) imaging in patients with Neuroblastoma and other Neuroendocrine Malignancies

abs# 265

Shakeel Modak

¹²⁴I-hu3F8 radioimmuno-positron emission tomography (PET) in patients with neuroblastoma and other GD2-positive malignancies: preliminary results on biodistribution, pharmacokinetics and tumor targeting

abs# 266

Atsuko Nakazawa

A High ALK expression is associated with an unfavorable histology in Neuroblastoma.

abs# 267

Meng Yao Lu

Feasibility of applying F¹⁸-DOPA hybrid MR-PET to follow-up of neuroblastoma patients

abs# 268

Divya Sahu

Co-expression network analysis reveals long non-coding RNA *SNHG1* as a novel biomarker in neuroblastoma

abs# 269

Gudrun Schleiermacher

Post surgical ¹²³I-MIBG SPECT/CT in neuroblastoma

abs# 270

Gudrun Schleiermacher

High-risk neuroblastoma without *MYCN* amplification in patients between 12 and 18 months: Is there a hidden low-risk patient group?

abs# 271

Katarzyna Szewczyk

The detection and quantification of neuroblastoma metastases in bone marrow using plasmids-targets as standards in QRT-PCR

abs# 272

Clare J. Twist

Validation of image-defined risk factor (IDRF) assignment in patients with intermediate-risk neuroblastoma: a report from the Children's Oncology Group study ANBL0531

abs# 273

Godelieve Tytgat

Epithelial to mesenchymal transition and minimal residual disease monitoring in neuroblastoma

abs# 274

Sam Volchenbom

Computer-assisted Curie scoring for Metaiodobenzylguanidine (mIBG) Scans in Patients with Neuroblastoma

abs# 275

Kristoffer von Stedingk

Lack of adaptive immunity markers is associated with early death amongst high-risk neuroblastomas

abs# 276

Larry L Wang

High-MKI neuroblastomas - MYC-family-driven tumors with augmented expression of MYCN/MYC protein behaves more aggressively than Non-MYC-family-driven tumors: a report from the Children's Oncology Group

abs# 277

Daniel Weiser

XPO1 is overabundant in patients with neuroblastoma at ultra-high-risk for treatment failure: rationale for refined diagnostic risk stratification and targeted therapy

abs# 278

Akihiro Yoneda	Incidence of stage IV neuroblastoma patients 2-5 years of age was increased after the cessation of mass screening in Japan	abs# 279
Elise Young	Molecular Karyotyping in Neuroblastoma – time to stop G-banding.	abs# 280
Clarke Anderson	Neural stem cell-mediated enzyme/prodrug therapy for neuroblastoma: translation to the clinic	abs# 281
Giuseppe Barone	A comprehensive preclinical study of ALK inhibitors for the efficacious treatment of $ALK^{F1174L}/MYCN$ -driven neuroblastoma	abs# 282
Giuseppe Barone	The CHK1 inhibitor CCT244747, alone and in combination with gemcitabine, is active against p53 deficient models of neuroblastoma resistant to chemotherapy.	abs# 283
Laurel T. Bate-Eya	High efficacy of the BCL-2 inhibitor venetoclax (ABT-199) in neuroblastoma and rational for combination therapy.	abs# 284
Jeffrey Bond	Neuroblastoma drug response profiles are associated with gene expression profiles	abs# 285
Mario Capasso	A high-throughput drug screening of FDA approved anti-cancer compounds suggests candidate tyrosine kinase inhibitors for repositioning in neuroblastoma therapy	abs# 286
Emmy Dolman	ITCC Biology: pre-clinical targeted drug development for high-risk pediatric cancers	abs# 287
Andrea Flynn	Effects on tumor cells and the immune microenvironment may both contribute to the anti-tumor activities of DFMO in neuroblastoma pre-clinical models	abs# 288
Jennifer H Foster	Targeting NEDD8: a novel approach to treating neuroblastoma	abs# 289
Laura D. Gamble	Targeting the polyamine pathway in combination with conventional chemotherapy for the treatment of childhood neuroblastoma	abs# 290
Sina Gogolin	Targeting cell cycle and transcriptional CDKs using Roniciclib leads to significant high cell death in MYCN/MYC-activated neuroblastoma cells	abs# 291
Mitsuteru Hiwatari	Identification of novel pathways and molecules able to down regulate oncogenes expression by <i>in vitro</i> drug screening approaches in neuroblastoma cells.	abs# 292
Michael M Song	Cell lines (CLs) and patient derived xenografts (PDXs) established from post-mortem neuroblastoma samples display heterogeneity in sensitivity to chemotherapeutic agents commonly utilized in the treatment of high-risk neuroblastoma patients.	abs# 293
Keri A Streby	Enhancing ^{131}I -mIBG radiation therapy with oncolytic HSV1716 and NAT gene therapy in high-risk neuroblastoma	abs# 294
Sharon J. Diskin	Common germline variants at <i>MLF1</i> and <i>CPZ</i> loci associated with neuroblastoma susceptibility	abs# 295
Angelika Eggert	Mutational dynamics between primary and relapse neuroblastoma involve the Hippo/YAP1 pathway and genes relevant for epithelial-mesenchymal transition	abs# 296
Ji Won Lee	Comprehensive analysis of neuroblastoma using high depth cancer gene panel sequencing	abs# 297
Tao Liu	Suppressing the expression of a single novel long noncoding RNA leads to neuroblastoma regression or eradication	abs# 298
Dries Rombaut	Long non-coding RNAs as novel components in the TP53 pathway	abs# 299

Gudrun Schleiermacher

Genomic profiling in low and intermediate risk neuroblastoma to refine treatment stratification and improve patient outcome – LINES: a SIOPEN Trial

abs# 300

Gudrun Schleiermacher

Genomic profiling using circulating free tumor DNA highlights heterogeneity in neuroblastoma

abs# 301

Robert W Schnepf

The chromatin associated protein JARID2 is a novel LIN28B-Influenced target in neuroblastoma

abs# 302

Masatoshi Takagi

Loss of *ATM* function confers risk for advanced stage neuroblastoma but provides a therapeutic target for poly-ADP ribose polymerase inhibitors

abs# 303

Ya-Hui Tsai

Investigation on the miRNA signature in retinoic acid-resistant neuroblastoma cells as novel therapeutic targets

abs# 304

Christophe Van Neste

Integrated network analysis of G-quadruplex and replicative stress related genes as sources for neuroblastoma genomic instability

abs# 305

Jun Yang

The histone demethylase KDM5A regulates p53 function via a translation mechanism

abs# 306

Alan Van Goethem

Identification of non-invasive biomarkers for treatment response in neuroblastoma by circulating miRNA profiling

abs# 307

Gareth Veal

Busulfan and melphalan pharmacokinetics in high-risk neuroblastoma patients treated on the HR-NBL1/SIOPEN trial

abs# 308

Gareth J Veal

Clinical follow-up of high-risk neuroblastoma patients receiving individualised 13-cis-retinoic acid based on pharmacological exposure as part of a national UK study

abs# 309

Daniel A Morgenstern

Providing information on clinical trials to parents of children with neuroblastoma: a novel liaison in a clinical nurse specialist role.

abs# 310

Clare J. Twist

Premature physal closure following prolonged fenretinide administration in patients with neuroblastoma

abs# 311

Matthew D Aldridge

Establishment of a reproducible methodology and results for molecular radiotherapy dosimetric assessment of ¹⁷⁷Lu-DOTATATE in neuroblastoma

abs# 312

Julien Fleurence

An anti-O-acetylated GD2 ganglioside antibody for the immunotherapy of High – Grade Diffuse Glioma in children

abs# 314

Mark N Gaze

Immunohistochemical evaluation of target expression in high-risk neuroblastoma samples to facilitate optimisation of molecular radiotherapy

abs# 315

Tomoro Hishiki

Primary tumor resection after high dose chemotherapy with autologous hematopoietic stem cell transplantation is a safe and feasible option. A report from the Japanese neuroblastoma study group (JNBSG)

abs# 316

Tomoko Iehara

Opsoclonus-myooclonus syndrome in neuroblastoma: A report from the Japan Neuroblastoma Study Group (JNBSG)

abs# 317

Minori MI Ishii

Combination therapy of highly activated natural killer cells and anti-disialoganglioside (GD2) antibody for Neuroblastoma: An experimental study

abs# 318

Merel Jans

Analysis of surgery for Neuroblastoma in The Netherlands

abs# 319

Denis Kachanov

Low-risk neuroblastoma in Russia: therapy results and prognostic factors

abs# 320

- Min H Kang**
Pharmacokinetics (PK) of 13-cis Retinoic Acid in COG Phase III Neuroblastoma Studies *abs# 321*
- Shinsuke Kataoka**
Long term survival after KIR ligand incompatible allogeneic cord blood transplantation as a salvage therapy for relapsed stage IV neuroblastoma *abs# 322*
- Anatoly A P Kazantsev**
Treatment high-risk neuroblastoma. *abs# 323*
- Ruth Ladenstein**
Prognostic Factors in stage 4 neuroblastoma patients treated with Busulphan-Melphalan. Report from the European High Risk Neuroblastoma HR-NBL1/SIOPEN Trial. *abs# 324*
- Daniel A Morgenstern**
Primary tumour response to busulfan/melphalan high-dose chemotherapy in patients with high-risk neuroblastoma: a pilot study. *abs# 325*
- Daniel A Morgenstern**
Engraftment following busulfan/melphalan (BuMel) high-dose chemotherapy for high-risk neuroblastoma. A report from the HR-NBL-1/SIOPEN trial. *abs# 326*
- Atsushi Narita**
Phase I study of anti-GD2 antibody ch14.18/CHO long term infusion in recurrent or refractory neuroblastoma patients in Japan *abs# 327*
- Sajid Qureshi**
Complication of surgery for abdominal neuroblastoma: Chyle Leak *abs# 328*
- Elizabeth Roundhill**
Expression, trafficking and biological significance of mitochondrial MRP1 in neuroblastoma. *abs# 329*
- Gudrun Schleiermacher**
OMS/DES 2011: a Multinational European Trial for Children with Opsoclonus Myoclonus Syndrome *abs# 330*
- Hiroyuki Shichino**
Phase I trial of perifosine monotherapy in patients with relapsed or refractory neuroblastoma *abs# 331*
- Nikolai Siebert**
Generation of a new bicistronic DNA vaccine encoding for tyrosine hydroxylase and IL-15 to induce an active immune response against neuroblastoma *abs# 332*
- Stefania Sorrentino**
Spinal canal invasion in peripheral neuroblastic tumors. Study design and preliminary results of a prospective SIOPEN Study Registry. *abs# 333*
- Ryota Souzaki**
Creating Three-Dimensional full size model based on preoperative CT images for laparoscopic adrenalectomy and liver biopsy in a case demonstrating adrenal neuroblastoma with liver metastasis *abs# 334*
- Godelieve Tytgat**
131Iodine-metaiodobenzylguanidine (131I-MIBG) and autologous stem cell transplantation harvesting and hematological reconstitution in high-risk neuroblastoma patients. *abs# 335*
- Keith Wheatley**
BEACON-2: design of a SIOPEN/ITCC multi-arm multi-stage (MAMS) trial for relapsed neuroblastoma *abs# 336*
- Aleksandra Wiczorek**
The role of image defined risk factor (IDRF) in evaluation of the risk of post-surgical kidneys dysfunction in children with neuroblastoma *abs# 337*
- Darrell J Yamashiro**
Targeting activating transcription factor 5 (ATF5) in neuroblastoma with a novel dominant negative inhibitor *abs# 338*
- Jinhua Zhang**
A research of the induction and differentiation therapy for neuroblastoma in children *abs# 339*
- Maxi Zumpe**
Generation of new DNA- and protein vaccines for active immunotherapy against *MYCN*-expressing neuroblastoma *abs# 340*

- Carmen Dorneburg**
Boolean modeling identifies Greatwall/*MASTL* as an important regulator in the AURKA network of neuroblastoma abs# 341
- Simon Durand**
Growth advantage and oncogene addiction of neuroblastoma cells bearing an ALK mutation abs# 342
- Marco Gualandi**
Impact of Neuroblastoma recurrent mutations on embryonic sympatho-adrenal development abs# 343
- Naonori Kawakubo**
Natural antibody against neuroblastoma of the TH-MYCN transgenic mice has CDC activity abs# 344
- Venkatadri Kolla**
MYCN Amplicon in Neuroblastoma (NB) Cell Lines abs# 345
- Zhihui Liu**
Identification of CASZ1 nuclear export signal (NES) reveals potential mechanism for loss of CASZ1 tumor suppressor activity in neuroblastoma (NB) abs# 346
- Jelena Milosevic**
PPM1D/Wip1, the candidate gene on 17q contributing to neuroblastoma development abs# 347
- Katharina Batzke**
Modulation of immune responses and radioresistance by neuroblastoma-derived and host-derived TrkB-target Galectin-1 abs# 348
- Zhi Xiong Chen**
A non-canonical tumor suppression pathway identified in neuroblastoma – a new paradigm for personalized treatment and prognosis abs# 349
- Johanna Dzieran**
MYCN-induced miR-18a interferes with estrogen and NGF signaling to maintain an undifferentiated and more aggressive phenotype in neuroblastoma abs# 350
- Selene Elifio-Esposito**
NPY/NPY5R copy number increases in relapsing neuroblastoma abs# 351
- Mona Friedrich**
MYCN-dependent regulation of gene expression during the cell cycle in neuroblastoma cells abs# 352
- Jixuan Gao**
The ABC transporter ABCE1 is a therapeutic target in neuroblastoma abs# 353
- Giuseppe Giannini**
The Poly (ADP-ribose) polymerase inhibitor olaparib causes mitotic catastrophe in MYCN amplified neuroblastoma by enhancing replication stress abs# 354
- Sabine Hartlieb**
Alternative lengthening of telomeres in primary neuroblastoma specimens – a genomic, epigenomic & proteomic approach abs# 355
- Charlotte Haunch-Smith**
Characterisation of neuroblastoma cells isolated from bone marrow aspirates of children with stage 4 disease at diagnosis: an NCRI CCL CSG Neuroblastoma Group Study. abs# 356
- Zhongyan Hua**
PI3K and MAPK pathways mediate the BDNF/TrkB-increased migration and invasion in Neuroblastoma cells abs# 357
- Shinya Ikematsu**
Inhibition of the growth factor midkine in neuroblastoma by an Okinawan agricultural product abs# 358
- Niloufar Javanmardi**
Neuroblastoma: telomere elongation is responsible for aggressive behavior abs# 359
- Maria Kavallaris**
Stathmin mediates neuroblastoma metastasis in a tubulin-independent manner via RhoA/ROCK signalling and enhanced transendothelial migration abs# 360
- Patrick Kim**
Combination of HDAC and mitochondrial-targeted metabolism inhibitors exhibits strong therapeutic synergy *in vitro* and *in vivo* against neuroblastoma abs# 361

Satoshi Kishida

The involvement of Midkine, a growth factor exacerbating cisplatin-induced nephrotoxicity, in cisplatin resistance of neuroblastoma cells

abs# 362

Shinichi Kiyonari

Identification of new synthetic lethal genes in *MYCN*-amplified neuroblastoma cells

abs# 363

Jayne Murray

Suppression of Multidrug resistance protein 4 inhibits neuroblastoma growth both *in vitro* and *in vivo*

abs# 364

Ganna Oliynyk

MYCN mediates metabolic plasticity in childhood neuroblastoma

abs# 365

Annalisa Pezzolo

GOLPH3 regulates Golgi shape and is activated by DNA damage in neuroblastoma cell lines

abs# 366

Navin Pinto

Patterns of PD-1, PD-L1 and PD-L2 Expression in Neuroblastoma

abs# 367

María Victoria Ruiz Pérez

Targeting fatty acid synthesis to induce neuroblastoma differentiation

abs# 368

Alica Torkov

Blinding the CYCLOPS – Neuroblastoma vulnerabilities unveiled by genomic loss

abs# 369

Sieu L Tran

Elevated expression of dyskerin is a potential therapeutic target with a telomerase-independent role in *Myc/N-Myc*-driven neuroblastoma

abs# 370

Veronica Veschi

Epigenetic siRNA and chemosensitivity screens identify a vulnerability to SETD8 inhibition through reactivation of p53 canonical pathway in Neuroblastoma

abs# 371

My D Vu

The expression of AT Rich Interactive Domain 1A (*ARID1A*) in Neuroblastoma

abs# 372

Amber K Weiner

Integrative approach to define the cell surface landscape in neuroblastoma

abs# 373

Pei-Yi Wu

Calreticulin-dependent VEGF expression promotes neuroblastoma differentiation

abs# 374

Denise Yu

MYCN promotes neuroblastoma malignancy by establishing a regulatory circuit with transcription factor AP4

abs# 375

Tina Zheng

Human stem cell models for relapse neuroblastoma

abs# 376

TRANSPORT FROM CAIRNS CONVENTION CENTRE TO TJAPUKAI

7:15pm - 7:45pm

TJAPUKAI CAIRNS DINNER & SHOW OR DINNER ALONE

7:45pm - 9:45pm

Tjapukai Aboriginal Cultural Park

TRANSPORT FROM TJAPUKAI TO CONFERENCE HOTELS

9:45pm - 10:15pm

PROGRAM

WEDNESDAY, 22 JUNE, 2016

KEYNOTE 3 - KIMBERLY STEGMAIER

8:30am - 9:15am

Chair: Andy Pearson

Hall A

8:30am **Kimberly Stegmaier**
Emerging epigenetic targets in *MYCN*-amplified neuroblastoma

abs# 74

PLENARY SESSION 3

9:15am - 10:20am Hall A

Chairs: Angelika Eggert & Godfrey Chan

9:15am **Rogier Versteeg**
Neuroblastoma is bi-phasic and includes classical neuro-epithelial cells and chemo-resistant mesenchymal cells

abs# 75

9:31am **Pauline Depuydt**
Distal chromosome 6q-deletion defines a subgroup of ultra-high risk neuroblastoma patients

abs# 76

9:47am **Yael P Mosse**
Chemical proteomics defines kinome responses to ALK inhibition in neuroblastoma

abs# 77

10:03am **Shahab Asgharzadeh**
Enhancing efficacy of immune checkpoint blockade with anti-macrophage targeted therapy

abs# 78

MORNING TEA

10:20am - 11:00am

Exhibition Area

PARALLEL 9 - MYCN AND TUMOUR BIOLOGY

11:00am - 12:15pm

Chairs: Isabelle Janoueix-Lerosey & Kenji Kadomatsu

Hall A

11:00am **Giovanni Perini**
Altering the MYCN/MAX ratio in a drosophila MYCN model leads to homeotic transformation of the eye to wing through deregulation of specific HOX genes

abs# 80

11:15am **Johan van Nes**
Identification and reprogramming of mesenchymal-type cells in neuroblastoma

abs# 81

11:30am **Marie Arsenian-Henriksson**
Induction of a metabolic switch in neuroblastoma and in other human cancer types upon targeting MYC

abs# 82

11:45am **Andrew E Tee**
The histone methyltransferase DOT1L induces neuroblastoma progression by regulating gene transcription

abs# 83

12:00pm **Angela Bellini**
Frequency of high and low level clonal *ALK* mutations in high risk neuroblastoma patients. A SIOOPEN study

abs# 84

PARALLEL 10 - HIGH RISK NEUROBLASTOMA

11:00am - 12:15pm

Chairs: Purna Kurkure & Lisa Diller

Meeting room 1 & 2

- | | | |
|---------|--|----------------|
| 11:00am | <p>Thorsten Simon
I-131-meta-iodobenzylguanidine therapy improves survival in high-risk neuroblastoma patients with mIBG positive residual metastatic disease</p> | <i>abs# 85</i> |
| 11:15am | <p>Adela Cañete
Did we improve results in infants with MYCN Amplified Neuroblastoma? Comparison of treatment strategy and outcomes in INES 99.4 and HR-NBL1/ SIOPEN. A SIOPEN Study</p> | <i>abs# 86</i> |
| 11:30am | <p>Meaghan Granger
Myeloablative busulfan/melphalan (BuMel) consolidation following induction chemotherapy for patients with high-risk neuroblastoma. A Children's Oncology Group (COG) study</p> | <i>abs# 87</i> |
| 11:45am | <p>Giselle Sholler
DFMO maintains remission and increases overall survival in high risk neuroblastoma: results of a phase II prevention trial</p> | <i>abs# 88</i> |
| 12:00pm | <p>Thorsten Simon
The benefit of myeloablative chemotherapy with autologous stem cell transplantation in high-risk neuroblastoma patients is stable during long term follow-up. Results of the NB97 trial</p> | <i>abs# 89</i> |

FREE AFTERNOON

OPTIONAL REEF TRIP TO GREEN ISLAND 12:15 – 17:20

12:15pm - 5:20pm

Lunch boxes can be collected in the ground floor foyer.

DINNER ALONE

PROGRAM

THURSDAY, 23 JUNE, 2016

ANZCHOG WELCOME

9:00am - 9:10am

Hall A

PLENARY SESSION 4

9:10am - 10:30am

Chairs: Gudrun Schleiermacher & Sue Cohn

Hall A

Sponsored by

APEIRON
BIOLOGICS

9:10am

Julie R Park

A Phase 3 randomized clinical trial (RCT) of tandem myeloablative autologous stem cell transplant (ASCT) using peripheral blood stem cell (PBSC) as consolidation therapy for high-risk neuroblastoma (HR-NB): A Children's Oncology Group (COG) study

abs# 90

9:26am

Rajen Mody

Phase II randomized trial of irinotecan/temozolomide (I/T) with temsirolimus (TEM) or dinutuximab plus granulocyte colony stimulating factor (DIN/GMCSF) in children with refractory or relapsed neuroblastoma: a report from the Children's Oncology Group (COG)

abs# 91

9:42am

Mark A Applebaum

Second malignancies in patients with neuroblastoma: a report from the international neuroblastoma risk group project

abs# 92

9:58am

Ulrike Pötschger

The way towards an international mIBG skeletal score for high risk neuroblastoma: the statistical perspective

abs# 93

10:14am

Ruth Ladenstein

Final results of the randomised short term infusion (STI) of ch14.18/CHOmAB immunotherapy in combination with Aldesleukin: a report on outcome and toxicities from the HR-NBL1/SIOPEN trial

abs# 94

MORNING TEA

10:30am - 11:00am

Exhibition Area

PARALLEL 11 - BIOMARKERS AND NOVEL APPROACHES

11:00am - 12:30pm

Meeting room 1 & 2

Chairs: Per Kogner & Pat Reynolds

- 11:00am **Iedan Verly**
Catecholamine metabolites: novel diagnostic insight, correlations with biological features and prediction of clinical outcome in patients with neuroblastoma *abs# 95*
- 11:15am **Anne Hakkert**
High frequency of Cytosine to Adenine mutations in neuroblastoma correlates with genomic aberrations in 8-Oxo-Guanine repair pathway *abs# 96*
- 11:30am **Geertrui Denecker**
The FOXM1 target gene BIRC5 (survivin) is a top ranked dosage sensitive gene located on the common large copy number 17q gained segment in neuroblastoma. *abs# 97*
- 11:45am **Belamy B Cheung**
Identification of novel small molecule compounds to restore sensitivity to trophic factor withdrawal in MYCN-initiated death resistant cells *abs# 98*
- 12:00pm **Sabine Taschner-Mandl**
Metronomic Topotecan impedes tumor growth of MYCN-amplified neuroblastoma cells *in vitro* and *in vivo* by therapy induced senescence *abs# 99*
- 12:15pm **Michael M Song**
High MYCN, low MYC, low CERS4, and low anti-apoptotic BCL2 gene family expression are associated with sensitivity to fenretinide in neuroblastoma cell lines and PDXs *abs# 100*

PARALLEL 12 - IMMUNOTHERAPY AND EARLY PHASE TRIALS

11:00am - 12:30pm

Meeting room 3 & 4

Chairs: Daniel Morgenstern & Rajen Mody

- 11:00am **Annette Kuenkele**
Preclinical assessment of CD171-directed CAR T cell adoptive therapy for childhood neuroblastoma: CE7 epitope target safety and product manufacturing feasibility *abs# 101*
- 11:15am **Holger N Lode**
Phase II clinical trial with long-term infusion of anti-GD₂ antibody ch14.18/CHO in combination with interleukin-2 (IL2) showed clinical efficacy and improved toxicity in patients with high risk neuroblastoma. *abs# 102*
- 11:30am **Sara M. Federico**
Humanized anti-gd2 antibody (hu14.18k322a) with Chemotherapy +/- parental natural killer (nk) cells in children with recurrent/ refractory Neuroblastoma *abs# 103*
- 11:45am **Shahab Asgharzadeh**
Tumor-associated macrophage polarization state and the dynamic nature of PDL1 expression in neuroblastomas *abs# 104*
- 12:00pm **Julie R Park**
Engineered Neuroblastoma Cellular Immunotherapy (ENCIT)-01: A phase 1 study of autologous T-cells lentivirally transduced to express CD171-specific Chimeric Antigen Receptors (CAR) for recurrent/refractory high-risk neuroblastoma (HR-NB) *abs# 105*
- 12:15pm **Steven G. DuBois**
Phase II study of alisertib, irinotecan, and temozolomide in children with relapsed and refractory neuroblastoma: A report from the New Approaches to Neuroblastoma Therapy (NANT) consortium *abs# 106*

NEUROBLASTOMA UPDATE - 1

11:00am - 12:30pm

Hall A

Chairs: Sue Cohn & Andy Pearson

11:00am	Sharon Diskin Overview of neuroblastoma epidemiology and genetic predisposition	abs# 107
11:20am	Frank Speleman Actionable genomic mutations	abs# 108
11:40am	Susan Cohn Updates on the International Neuroblastoma Risk Group (INRG). Classification System and Interactive INRG Database (iINRGdb)	abs# 109
12:00pm	Gudrun Schleiermacher Overview of treatment for low- and intermediate-risk patients	abs# 110

LUNCH

12:30pm - 1:30pm

Exhibition Area

FOLLOW-UP ANRA ADVISORY BOARD MEETING

12:30pm - 1:30pm

Meeting room 3 & 4

INDUSTRY SPONSORED WORKSHOP: UNITED THERAPEUTICS

12:45pm - 1:25pm

Meeting room 1 & 2

PARALLEL 13 - GENOME WIDE ANALYSIS AND GENETIC VARIATION

1:30pm - 3:30pm

Meeting room 3 & 4

Chairs: Frank Westermann & Katleen De Preter

1:30pm	Mario Capasso Whole exome and deep targeted sequencing of clinically aggressive neuroblastomas reveal recurrent somatic mutations in pathways involved in cancer progression	abs# 111
1:45pm	Sharon J. Diskin Identification of germline mutations in 776 children with neuroblastoma	abs# 112
2:00pm	Fakhera Ikram Fusion-transcripts are associated with an unfavourable phenotype in neuroblastoma	abs# 113
2:15pm	Paul Deveau Clonal reconstruction in neuroblastoma shows enrichment of mutations in cell survival and DNA-repair pathways at relapse	abs# 114
2:30pm	Frank Westermann Chromosomal rearrangements juxtapose active enhancer elements to oncogenes in high-risk neuroblastoma	abs# 115
2:45pm	Carolina Rosswog Molecular risk assessment of neuroblastoma patients eliminates the necessity of clinical prognostic markers	abs# 116
3:00pm	Mark A Applebaum Genetic variants in <i>BARD1</i> and <i>KIF15</i> are associated with <i>MYCN</i> -amplification in neuroblastoma	abs# 117
3:15pm	Navin Pinto Pharmacogenetics of treatment response in patients with high-risk neuroblastoma, a Children's Oncology Group study	abs# 118

PARALLEL 14 - CLINICAL AWARDS SESSION

1:30pm - 3:30pm

Chairs: Holger Lode & Jed Nuchtern

Meeting room 1 & 2

Sponsored by



GILEAD

1:30pm	Lucas Moreno Predicting “early” relapse/progression/death in children with INRGSS Stage M neuroblastoma using clinical and biologic factors: An INRG database analysis	<i>abs# 119</i>
1:45pm	Meredith S Irwin Revised Children’s Oncology Group (COG) risk stratification incorporating the international neuroblastoma risk group staging system	<i>abs# 120</i>
2:00pm	Ji Won Lee High-dose ¹³¹ I-MIBG treatment incorporated into tandem HDCT/auto-SCT for high-risk neuroblastoma: Results of SMC NB-2009 study	<i>abs# 121</i>
2:15pm	Kelly Huibregtse Incidence and risk factors for secondary malignancy in patients with neuroblastoma after treatment with ¹³¹ I-metaiodobenzylguanidine	<i>abs# 122</i>
2:30pm	Pablo Berlanga Central nervous system relapses in patients with high-risk neuroblastoma: the SIOOPEN experience	<i>abs# 123</i>
2:45pm	Andras Heczey Autologous T cells expressing a GD2 specific chimeric antigen receptor with CD28 and OX40 costimulatory endodomains for children with neuroblastoma	<i>abs# 124</i>
3:00pm	Holger N Lode Killer-cell Ig-like receptor (KIR) haplotypes and Fc γ -receptor polymorphisms correlate with antibody-dependent cell-mediated cytotoxicity levels and survival of high-risk relapsed/refractory neuroblastoma patients treated by long-term infusion of anti-GD ₂ antibody ch14.18/CHO in combination with interleukin-2 (IL-2).	<i>abs# 125</i>
3:15pm	Araz Marachelian A Phase I Study of Lenalidomide in Combination with ch14.18 and isotretinoin in Patients with Refractory/Recurrent Neuroblastoma (RR-NB): New Approaches to Neuroblastoma Therapy (NANT) Consortium Trial	<i>abs# 126</i>

NEUROBLASTOMA UPDATE - 2

1:30pm - 3:30pm Hall A

Chairs: Sue Cohn & Andy Pearson

1:30pm	Julie Park Overview of treatment for high-risk patients	<i>abs# 127</i>
2:00pm	Lucas Moreno Overview of treatment for relapsed disease	<i>abs# 128</i>
2:30pm	Lisa Diller Long-term effect of treatment	<i>abs# 129</i>

AFTERNOON TEA

3:30pm - 4:00pm

Exhibition Area

KEYNOTE 4 – STEPHAN GRUPP

4:00pm - 4:45pm

Chair: Julie Park

Hall A

4:00pm	Stephan Grupp The CAR T cell revolution in cancer therapy	<i>abs# 130</i>
--------	---	-----------------

ANR CLOSING CEREMONY

4:45pm - 5:15pm

Chair: Michelle Haber

Hall A

CONFERENCE DINNER

7:00pm - 11:30pm

Hall 2

INDUSTRY SPONSORED WORKSHOPS

“EFFICACY AND SAFETY OF ch14.18/CHO IN NEUROBLASTOMA”

Monday 20th June 2016
12:45pm – 1:25pm
Meeting Room 1&2

Holger N. Lode, MD
Professor and Chair of Pediatrics University
Medicine Greifswald Germany Monday,



Immunotherapy directed against ganglioside GD2 emerges as an important cornerstone in multimodal treatment regimen of neuroblastoma. GD2 is ranked by the national cancer institute of the United States on position 12 of 79 tumor associated antigens and the clinically most advanced concept to exploit GD2 expression on neuroblastoma for therapeutic purposes is passive immunotherapy with monoclonal antibodies (MAB). Clinical efficacy of human/mouse chimeric MAB ch14.18 specific for GD2 was demonstrated in large multi-center clinical trials conducted by independent cooperative groups either used as monotherapy or in combination with cytokines. In Europe ch14.18 was remanufactured in Chinese hamster ovary cells (ch14.18/CHO) and was investigated in multi-center Phase I, II and III clinical trials in frontline treatment regimen and in patients with relapsed and refractory disease. In order to improve tolerability of the treatment, long term continuous infusion was evaluated suggesting that this is the preferred method of ch14.18 delivery. A summary of results of ch14.18/CHO therapy across clinical trials will be reviewed and discussed underlining efficacy and safety of this MAB for children with NB.

“Establishing a New Standard of Care for High-Risk Neuroblastoma Patients – our practical experience”

Thursday 23rd June 2016
12:45pm – 1:25pm
Meeting Room 1&2



We are delighted to invite you to attend the symposium sponsored by United Therapeutics Europe, Limited at this year's Advances in Neuroblastoma Research (ANR) 2016 Congress, entitled “Establishing a New Standard of Care for High-Risk Neuroblastoma Patients – our practical experience”.

The symposium will raise knowledge of Unituxin® (dinutuximab) as the only approved immunotherapy for the treatment of high-risk neuroblastoma, demonstrating the clinical risks and benefits of this therapeutic advance versus previous standard of care. It is an opportunity to examine the clinical application and role of Unituxin immunotherapy in

patients, and to share experience in current best-practice approaches to Unituxin treatment optimisation through a series of case studies.

The meeting will be co-chaired by two leading European experts in the management of high-risk neuroblastoma who also have experience using Unituxin immunotherapy.

- Dr Jaume Mora (Department of Hematology and Oncology, Hospital Sant Joan de Deu (HSJD) Barcelona, Spain)
- Dr Stergios Zacharoulis (Paediatric Oncology Consultant, Royal Marsden Hospital NHS Trust, Sutton, Surrey, UK)

We look forward to your attendance in what we hope will be an insightful, practical and enjoyable session.

Unituxin is not registered for use in Australia. Unituxin is approved by the European Commission and the US Food and Drug Administration for the treatment of high-risk neuroblastoma in paediatric patients.

A satellite symposium organised by United Therapeutics Europe, Limited (not included in the main event CME/CPD credit offering). ANR 2016 has provided space for this industry session. The programme was independently produced, not subject to review by ANR, and is not part of the scientific/educational programme offered by ANR 2016.

NEUROBLASTOMA PARENTS DAY

FRIDAY 24TH JUNE, 2016 TEA & COFFEE

08:30am - 09:00am

WELCOME AND OVERVIEW OF THE DAY'S AGENDA

09:00am - 09:10am

Chair: **Donna Drew**

Meeting room 6

HIGH STAKES, DIFFICULT CHOICES: NAVIGATING THE MAZE OF CANCER THERAPY

09:10am - 10:00am

Chair: **Donna Drew**

Meeting room 6

Donna Ludwinski, Solving Kids' Cancer

Making informed and strategic decisions about treatments creates a huge burden of responsibility for parents of children diagnosed with neuroblastoma. Information sources now range from oncologists and web-based medical journals to social media. The key elements of clinical research, and perspectives on past, present and future therapies provide the context for understanding current advances in research. With mutual trust and respect in the doctor-parent relationship, informed parents are best equipped for the difficult task of making choices for their child.

GENETICS

10:00am - 10:40am

Chair: **Donna Drew**

Meeting room 6

John Maris, The Children's Hospital of Philadelphia

MORNING TEA

10:40am - 11:00am

Mezzanine Level Foyer

PARALLEL - IMMUNOTHERAPY AND NEUROBLASTOMA

11:00am - 11:40am

Chair: **Toby Trahair**

Meeting room 6

Holger Lode, University of Medicine Greifswald

PARALLEL - NURSING SYMPOSIUM "BREAKING BAD NEWS"

11:00am - 11:40am

Chair: **Donna Drew**

Meeting room 5

Donna Ludwinski, Solving Kids' Cancer

Delivering bad news, and helping parents (and patients) absorb and cope with the bad news is a major challenge for medical professionals. This requires understanding the parent perspective of diagnosis, disease trajectory, informed consent, and managing family expectations in phase I and phase II trials. Nurses play an integral role in supporting parents transitioning from curative intent to palliative care in hospice and in decisions made in end-of-life care. Nursing delegates will have opportunity to share scenarios they faced with families receiving bad news for open discussion and learn from others' experience.

NEW THERAPIES

11:40am - 12:20pm

Chair: **Toby Trahair**

Julie Park, Seattle Children's Hospital

Meeting room 6

LUNCH

12:30pm - 1:30pm

Mezzanine Level Foyer

TARGETED RADIATION

1:30pm - 2:10pm

Chair: **Chris Williams**

Mark Gaze, University College Hospital London

Meeting room 6

SURVIVORSHIP AND LATE AFFECTS

2:10pm - 2:50pm

Chair: **Chris Williams**

Richard Cohn, Sydney Children's Hospital

Meeting room 6

AFTERNOON TEA

3:00pm - 3:20pm

Mezzanine Level Foyer

A FAMILY TELLS THEIR STORY

3:20pm - 4:00pm

Chair: **Donna Drew**

Meeting room 6

PANEL DISCUSSION

4:00pm - 6:00pm

Chair: **Glenn Marshall**

Panel: Donna Ludwinski, John Maris, Julie Park, Richard Cohn, Glenn Marshall, Sydney Children's Hospital, Toby Trahair, Sydney Children's Hospital

Meeting room 6

ROUND UP AND CLOSE

6:00pm - 6:05pm

Chair: **Donna Drew**

Meeting room 6

DINNER

6:05pm